BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32182216)

  • 1. NFATC4 promotes quiescence and chemotherapy resistance in ovarian cancer.
    Cole AJ; Iyengar M; Panesso-Gómez S; O'Hayer P; Chan D; Delgoffe GM; Aird KM; Yoon E; Bai S; Buckanovich RJ
    JCI Insight; 2020 Apr; 5(7):. PubMed ID: 32182216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quiescent Ovarian Cancer Cells Secrete Follistatin to Induce Chemotherapy Resistance in Surrounding Cells in Response to Chemotherapy.
    Cole AJ; Panesso-Gómez S; Shah JS; Ebai T; Jiang Q; Gumusoglu-Acar E; Bello MG; Vlad A; Modugno F; Edwards RP; Buckanovich RJ
    Clin Cancer Res; 2023 May; 29(10):1969-1983. PubMed ID: 36795892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MET overexpression in ovarian cancer via CD24-induced downregulation of miR-181a: A signalling for cellular quiescence-like state and chemoresistance in ovarian CSCs.
    Kwon JE; Jang Y; Yun BS; Kang S; Kim YH; Kim BG; Cho NH
    Cell Prolif; 2024 May; 57(5):e13582. PubMed ID: 38030594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
    Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
    Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin.
    He M; Wu H; Jiang Q; Liu Y; Han L; Yan Y; Wei B; Liu F; Deng X; Chen H; Zhao L; Wang M; Wu X; Yao W; Zhao H; Chen J; Wei M
    Mol Oncol; 2019 Feb; 13(2):403-421. PubMed ID: 30536571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
    Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
    Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
    Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
    Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
    Li H; Zhang W; Niu C; Lin C; Wu X; Jian Y; Li Y; Ye L; Dai Y; Ouyang Y; Chen J; Qiu J; Song L; Zhang Y
    Int J Cancer; 2019 Oct; 145(7):1921-1934. PubMed ID: 30895619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ISG15 is downregulated by KLF12 and implicated in maintenance of cancer stem cell-like features in cisplatin-resistant ovarian cancer.
    Zhang Q; Wang J; Qiao H; Huyan L; Liu B; Li C; Jiang J; Zhao F; Wang H; Yan J
    J Cell Mol Med; 2021 May; 25(9):4395-4407. PubMed ID: 33797839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells.
    Escalona RM; Bilandzic M; Western P; Kadife E; Kannourakis G; Findlay JK; Ahmed N
    BMC Cancer; 2020 Oct; 20(1):960. PubMed ID: 33023532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer-associated mesothelial cells promote ovarian cancer chemoresistance through paracrine osteopontin signaling.
    Qian J; LeSavage BL; Hubka KM; Ma C; Natarajan S; Eggold JT; Xiao Y; Fuh KC; Krishnan V; Enejder A; Heilshorn SC; Dorigo O; Rankin EB
    J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
    Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
    Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
    [No Abstract]   [Full Text] [Related]  

  • 13. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.
    Abubaker K; Latifi A; Luwor R; Nazaretian S; Zhu H; Quinn MA; Thompson EW; Findlay JK; Ahmed N
    Mol Cancer; 2013 Mar; 12():24. PubMed ID: 23537295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy induces adaptive drug resistance and metastatic potentials via phenotypic CXCR4-expressing cell state transition in ovarian cancer.
    Lee HH; Bellat V; Law B
    PLoS One; 2017; 12(2):e0171044. PubMed ID: 28196146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
    Ramadoss S; Sen S; Ramachandran I; Roy S; Chaudhuri G; Farias-Eisner R
    Oncogene; 2017 Mar; 36(11):1537-1545. PubMed ID: 27694900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
    Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
    Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
    Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
    Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SET Domain-Containing Protein 4 Epigenetically Controls Breast Cancer Stem Cell Quiescence.
    Ye S; Ding YF; Jia WH; Liu XL; Feng JY; Zhu Q; Cai SL; Yang YS; Lu QY; Huang XT; Yang JS; Jia SN; Ding GP; Wang YH; Zhou JJ; Chen YD; Yang WJ
    Cancer Res; 2019 Sep; 79(18):4729-4743. PubMed ID: 31308046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VPS33B interacts with NESG1 to suppress cell growth and cisplatin chemoresistance in ovarian cancer.
    Ning Y; Zeng Z; Deng Y; Feng W; Huang L; Liu H; Lin J; Zhang C; Fan Y; Liu L
    Cancer Sci; 2021 May; 112(5):1785-1797. PubMed ID: 33788346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roflumilast enhances cisplatin-sensitivity and reverses cisplatin-resistance of ovarian cancer cells via cAMP/PKA/CREB-FtMt signalling axis.
    Gong S; Chen Y; Meng F; Zhang Y; Li C; Zhang G; Huan W; Wu F
    Cell Prolif; 2018 Oct; 51(5):e12474. PubMed ID: 30069985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.